{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:08:26Z","timestamp":1792541306716,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T00:00:00Z","timestamp":1608163200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anterior uveitis secondary to topical brimonidine administration is rare and not well-defined. In glaucoma patients using brimonidine, one must consider this phenomenon to avoid mis-diagnosis and over-treatment with topical steroids which in turn may increase intraocular pressure (IOP). This is the largest case series including the longest patient follow-up in the current literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Sixteen patients (26 eyes) with consultant diagnosed brimonidine-associated anterior uveitis in a tertiary referral glaucoma clinic presenting between 2015 and 2019 were included in this retrospective case series. Clinical records were taken for descriptive analysis. Main outcome measures were the key clinical features, and disease course (therapy, IOP control, patient outcome).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Key features were conjunctival ciliary injection and mutton fat keratic precipitation in all eyes. The findings were bilateral in 10 patients. Time between initiation of brimonidine treatment and presentation was 1\u2009week to 49\u2009months. Glaucoma sub-types were mostly pseudo-exfoliative and primary open angle glaucoma. Brimonidine treatment was stopped immediately. Additionally, topical corticosteroids were prescribed in 18 eyes and tapered down during the following 4\u2009weeks. Thirteen eyes did not need surgical or laser treatment (median follow-up time 15\u2009months). No patient showed recurrence of inflammation after cessation of brimonidine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This type of anterior uveitis is an uncommon but important manifestation which should always be considered in glaucoma patients on brimonidine treatment. Although treatable at its root cause, problems may persist, especially with respect to IOP control. The latter may necessitate glaucoma surgery after the resolved episode of the uveitis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-020-01762-w","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T10:13:44Z","timestamp":1608200024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Brimonidine-associated uveitis \u2013 a descriptive case series"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7989-9420","authenticated-orcid":false,"given":"Susanne","family":"Hopf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Mercieca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Prokosch-Willing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"key":"1762_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/IJG.0b013e3181132188","volume":"17","author":"EV Nguyen","year":"2008","unstructured":"Nguyen EV, Azar D, Papalkar D, McCluskey P. Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features. J Glaucoma. 2008;17:40\u20132.","journal-title":"J Glaucoma"},{"key":"1762_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0002-9394(00)00491-8","volume":"130","author":"DB Byles","year":"2000","unstructured":"Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol. 2000;130:287\u201391.","journal-title":"Am J Ophthalmol"},{"key":"1762_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/archopht.122.7.1063","volume":"122","author":"HI Becker","year":"2004","unstructured":"Becker HI, Walton RC, Diamant JI, Zegans ME. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol Chic Ill 1960. 2004;122:1063\u20136.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"key":"1762_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/09273948.2015.1037845","volume":"24","author":"J Beltz","year":"2016","unstructured":"Beltz J, Zamir E. Brimonidine induced anterior uveitis. Ocul Immunol Inflamm. 2016;24:128\u201333.","journal-title":"Ocul Immunol Inflamm"},{"key":"1762_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10792-012-9688-0","volume":"33","author":"MA Carrasco","year":"2013","unstructured":"Carrasco MA, Schlaen BA, Z\u00e1rate JO. Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye. Int Ophthalmol. 2013;33:557\u201360.","journal-title":"Int Ophthalmol"},{"key":"1762_CR6","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00417-013-2415-3","volume":"251","author":"A Casado","year":"2013","unstructured":"Casado A, Cabarga C, de la Fuente MA, Mu\u00f1oz-Negrete FJ. Suspected granulomatous anterior uveitis associated with brimonidine tartrate 0.2% and timolol maleate 0.5% ophthalmic solution. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2013;251:2659\u201360.","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"key":"1762_CR7","first-page":"670","volume":"17","author":"CA Cates","year":"2003","unstructured":"Cates CA, Jeffrey MN. Granulomatous anterior uveitis associated with 0.2% topical brimonidine. Eye Lond Engl. 2003;17:670\u20131.","journal-title":"Eye Lond Engl"},{"key":"1762_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.oftal.2018.05.005","volume":"93","author":"R Clemente-Tom\u00e1s","year":"2018","unstructured":"Clemente-Tom\u00e1s R, Arciniegas-Perasso CA, Herv\u00e1s-Hernandis JM, Garc\u00eda-Ibor F, Ruiz-Del R\u00edo N, Duch-Samper AM. Hypertensive acute granulomatous anterior uveitis as a side effect of topical brimonidine. Arch Soc Espanola Oftalmol. 2018;93:511\u20134.","journal-title":"Arch Soc Espanola Oftalmol"},{"issue":"Pt 6","key":"1762_CR9","first-page":"908","volume":"14","author":"R Goyal","year":"2000","unstructured":"Goyal R, Ram AR. Brimonidine tartarate 0.2% (Alphagan) associated granulomatous anterior uveitis. Eye Lond Engl. 2000;14(Pt 6):908\u201310.","journal-title":"Eye Lond Engl"},{"key":"1762_CR10","unstructured":"Hondeghem K, Augustinus B, De Smet MD. Bilateral granulomatous uveitis as a side effect of topical brimonidine: two case reports. Bull Soc Belge Ophtalmol. 2009:51\u20132."},{"key":"1762_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/bjo.2006.099085","volume":"91","author":"A Kahana","year":"2007","unstructured":"Kahana A, Marcet MM, Albert DM, Thliveris AT. Drug-induced cicatrising granulomatous conjunctivitis. Br J Ophthalmol. 2007;91:691\u20132.","journal-title":"Br J Ophthalmol"},{"key":"1762_CR12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/bjophthalmol-2011-300872","volume":"96","author":"CM McKnight","year":"2012","unstructured":"McKnight CM, Richards JC, Daniels D, Morgan WH. Brimonidine (Alphagan) associated anterior uveitis. Br J Ophthalmol. 2012;96:766\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 1","key":"1762_CR13","doi-asserted-by":"publisher","first-page":"S285","DOI":"10.1016\/j.mjafi.2014.09.009","volume":"71","author":"A Oli","year":"2015","unstructured":"Oli A, Joshi D. Interesting case of severe anterior uveitis caused by brimonidine eye drops. Med J Armed Forces India. 2015;71(Suppl 1):S285\u20136.","journal-title":"Med J Armed Forces India"},{"key":"1762_CR14","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S0181-5512(04)96285-7","volume":"27","author":"L Velasque","year":"2004","unstructured":"Velasque L, Ducousso F, Pernod L, Vignal R, Deral V. Anterior uveitis and topical brimonidine: a case report. J Fr Ophtalmol. 2004;27:1150\u20132.","journal-title":"J Fr Ophtalmol"},{"key":"1762_CR15","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jfo.2016.01.016","volume":"40","author":"A Comet","year":"2017","unstructured":"Comet A, Donnadieu B, Courjaret J-C, Gascon P, Denis D, Matonti F. Brimonidine and acute anterior granulomatous uveitis: a case report and literature review. J Fr Ophtalmol. 2017;40:e127\u20139.","journal-title":"J Fr Ophtalmol"},{"key":"1762_CR16","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.4103\/ijo.IJO_1427_19","volume":"67","author":"J Kattige","year":"2019","unstructured":"Kattige J, Konana VK, Babu K. Bilateral granulomatous uveitis in an elderly female. Indian J Ophthalmol. 2019;67:1391.","journal-title":"Indian J Ophthalmol"},{"key":"1762_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/01.icu.0000434534.32063.5c","volume":"24","author":"RS Moorthy","year":"2013","unstructured":"Moorthy RS, London NJS, Garg SJ, Cunningham ET. Drug-induced uveitis. Curr Opin Ophthalmol. 2013;24:589\u201397.","journal-title":"Curr Opin Ophthalmol"},{"key":"1762_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/jop.2015.0067","volume":"31","author":"H-Y Shin","year":"2015","unstructured":"Shin H-Y, Lee H-S, Lee YC, Kim S-Y. Effect of Brimonidine on the B cells, T cells, and cytokines of the ocular surface and aqueous humor in rat eyes. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2015;31:623\u20136.","journal-title":"J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther"},{"key":"1762_CR19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0002-9394(14)72966-6","volume":"118","author":"KC Chern","year":"1994","unstructured":"Chern KC, Meisler DM, Rockwood EJ, Lowder CY. Pseudoexfoliation syndrome masquerading as uveitis. Am J Ophthalmol. 1994;118:392\u20133.","journal-title":"Am J Ophthalmol"},{"key":"1762_CR20","first-page":"114","volume":"1181","author":"RW Beck","year":"1996","unstructured":"Beck RW, Moke P, Blair RC, Nissenbaum R. Uveitis associated with topical beta-blockers. Arch Ophthalmol Chic Ill 1960. 1996;1181:114\u20132.","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"key":"1762_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1869-5760-3-43","volume":"3","author":"NJ London","year":"2013","unstructured":"London NJ, Garg SJ, Moorthy RS, Cunningham ET. Drug-induced uveitis. J Ophthalmic Inflamm Infect. 2013;3:43.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1762_CR22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/ICU.0000000000000530","volume":"29","author":"RS Moorthy","year":"2018","unstructured":"Moorthy RS, Moorthy MS, Cunningham ET. Drug-induced uveitis. Curr Opin Ophthalmol. 2018;29:588\u2013603.","journal-title":"Curr Opin Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-020-01762-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T10:22:38Z","timestamp":1608200558000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01762-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1762"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01762-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"28 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the recommendations of the Declaration of Helsinki, and was authorized by the local ethics committee of Rhineland-Palatinate, Mainz (Germany). The patients gave informed written consent for data collection and analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"489"}}